PL3200815T3 - Sposoby i kompozycje do leczenia nowotworu - Google Patents

Sposoby i kompozycje do leczenia nowotworu

Info

Publication number
PL3200815T3
PL3200815T3 PL15847792T PL15847792T PL3200815T3 PL 3200815 T3 PL3200815 T3 PL 3200815T3 PL 15847792 T PL15847792 T PL 15847792T PL 15847792 T PL15847792 T PL 15847792T PL 3200815 T3 PL3200815 T3 PL 3200815T3
Authority
PL
Poland
Prior art keywords
cancer
compositions
treatment
methods
Prior art date
Application number
PL15847792T
Other languages
English (en)
Inventor
Alfredo PERALES-PUCHALT
Jose R. Conejo-Garcia
Original Assignee
The Wistar Institute Of Anatomy And Biology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Wistar Institute Of Anatomy And Biology filed Critical The Wistar Institute Of Anatomy And Biology
Publication of PL3200815T3 publication Critical patent/PL3200815T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C07K14/70564—Selectins, e.g. CD62
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
PL15847792T 2014-10-02 2015-09-30 Sposoby i kompozycje do leczenia nowotworu PL3200815T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462059068P 2014-10-02 2014-10-02
US201562202824P 2015-08-08 2015-08-08
EP15847792.7A EP3200815B1 (en) 2014-10-02 2015-09-30 Methods and compositions for treating cancer
PCT/US2015/053128 WO2016054153A1 (en) 2014-10-02 2015-09-30 Methods and compositions for treating cancer

Publications (1)

Publication Number Publication Date
PL3200815T3 true PL3200815T3 (pl) 2021-10-18

Family

ID=55631412

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15847792T PL3200815T3 (pl) 2014-10-02 2015-09-30 Sposoby i kompozycje do leczenia nowotworu

Country Status (16)

Country Link
US (4) US10259855B2 (pl)
EP (1) EP3200815B1 (pl)
CN (2) CN106999552B (pl)
CA (1) CA2989807C (pl)
CY (1) CY1125797T1 (pl)
DK (1) DK3200815T3 (pl)
ES (1) ES2870607T3 (pl)
HR (1) HRP20210705T1 (pl)
HU (1) HUE054673T2 (pl)
LT (1) LT3200815T (pl)
PL (1) PL3200815T3 (pl)
PT (1) PT3200815T (pl)
RS (1) RS61929B1 (pl)
SI (1) SI3200815T1 (pl)
SM (1) SMT202100273T1 (pl)
WO (1) WO2016054153A1 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016073456A1 (en) * 2014-11-04 2016-05-12 The Trustees Of The University Of Pennsylvania Methods and compositions of a follicle stimulating hormone receptor immunoreceptor or chimeric antigen receptor
EP3439698A1 (en) * 2016-04-05 2019-02-13 GlaxoSmithKline Intellectual Property Development Ltd Inhibition of tgfbeta in immunotherapy
IT201600101852A1 (it) * 2016-10-11 2018-04-11 Abresearch Srl Ligandi del recettore dell’ormone FSH nella diagnosi e nella terapia dei tumori
RU2755000C2 (ru) * 2016-10-11 2021-09-08 Онкогреен Тхерапеутикс Са Лиганды к рецептору фолликулостимулирующего гормона (FSH) в диагностике и лечении опухолей
IT201600101870A1 (it) * 2016-10-11 2018-04-11 Abresearch Srl Ligandi del recettore dell’ormone FSH nella diagnosi e nella terapia del neuroblastoma
WO2019028096A1 (en) 2017-08-02 2019-02-07 The Wistar Institute Of Anatomy And Biology METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
EP3676378A4 (en) 2017-08-31 2021-06-09 The New York Genome Center PROCEDURES AND COMPOSITIONS USING CRIMP-CPF1 AND PAIRED GUIDE-CRISPR-RNA FOR PROGRAMMABLE GENOMIC DELETIONS
EP3675878A4 (en) 2017-10-02 2021-06-16 Fred Hutchinson Cancer Research Center LUTEINIZING HORMONE RECEPTOR BINDERS AND LUTEINIZING HORMONAGONISTS FOR IDENTIFICATION, EXPANSION, ABLATION AND MODIFICATION OF PRIMITIVE STEM CELL POPULATIONS
US20190211109A1 (en) * 2018-01-05 2019-07-11 Maxcyte, Inc. Chronic car treatment for cancer
AU2019375036A1 (en) * 2018-11-05 2021-06-03 Centre Hospitalier Universitaire Vaudois Humanized and variant TGF-beta1 specific antibodies and methods and uses thereof
WO2020146233A1 (en) * 2019-01-07 2020-07-16 H. Lee Moffitt Cancer Center And Research Institute Inc. Foxp1-ablated chimeric cells
MX2021009186A (es) * 2019-01-30 2021-09-08 Wistar Inst Captadores biespecificos de linfocitos t codificados por adn que se dirigen a antigenos de cancer y metodos de uso en tratamientos contra cancer.
JP2022526187A (ja) * 2019-04-12 2022-05-23 エモリー ユニバーシティー 造血細胞の細胞傷害性を促進するための組成物及び方法
US20230107770A1 (en) * 2020-02-20 2023-04-06 H. Lee Moffitt Cancer Center And Research Institute, Inc. Method of enhancing immunotherapy using er stress pathway inhibitors
US20240101626A1 (en) * 2021-02-12 2024-03-28 Kar Muthumani Consensus prostate antigens, nucleic acid molecules encoding the same, and vaccines and uses comprising the same
CN115975056B (zh) * 2023-02-07 2023-12-01 徐州医科大学 利用天然蛋白tsh作为抗原结合位点构建靶向tshr的car-t细胞

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5702702A (en) 1992-03-30 1997-12-30 The Wistar Institute Of Anatomy And Biology Modified cytotoxic tall cell line and compositions and methods for manufacture and use thereof as therapeutic reagents for cancer
HU230364B1 (hu) 2001-11-21 2016-03-29 The Trustees Of The University Of Pennsylvania Simian adenovírus nukleinsav és aminosav-szekvencia, azt tartalmazó vektorok, és eljárások annak alkalmazására
US7081446B2 (en) 2002-01-31 2006-07-25 The Trustees Of Columbia University In The City Of New York Long-acting follicle stimulating hormone analogues and uses thereof
AU2003270063A1 (en) 2002-09-04 2004-03-29 The Trustees Of The University Of Pennsylvania Immune cell receptor ligand and immune cell receptor
EP2000160A3 (en) 2002-10-30 2009-03-11 Gambro Lundia AB Method and apparatuses for determining the efficiency of dialysis
DE602005017743D1 (de) 2004-01-23 2009-12-31 Angeletti P Ist Richerche Bio Impfstoffträger für schimpansen-adenovirus
AU2006210443B2 (en) 2005-02-03 2011-01-27 Benitec, Inc. RNAi expression constructs
GB0725201D0 (en) * 2007-12-24 2008-01-30 Asterion Ltd Peptide fusion proteins
AU2009206212B2 (en) 2008-01-24 2014-01-16 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Lytic domain fusion constructs and methods of making and using same
EP2090322A1 (en) 2008-02-18 2009-08-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of fsh receptor ligands for diagnosis and therapy of cancer
SG10201407908VA (en) * 2008-12-19 2015-01-29 Macrogenics Inc Covalent diabodies and uses thereof
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US9708384B2 (en) 2011-09-22 2017-07-18 The Trustees Of The University Of Pennsylvania Universal immune receptor expressed by T cells for the targeting of diverse and multiple antigens
WO2013063019A1 (en) 2011-10-28 2013-05-02 The Wistar Institute Of Anatomy And Biology Methods and compositions for enhancing the therapeutic effect of anti-tumor t cells
JP2016506373A (ja) * 2012-11-15 2016-03-03 エスペランス ファーマシューティカルズ， インコーポレイテッド 卵胞刺激ホルモン（ｆｓｈ）／溶解ドメイン融合コンストラクト及びその作製及び使用の方法
CN103509121B (zh) * 2012-11-22 2015-01-28 苏州康宁杰瑞生物科技有限公司 一种fsh融合蛋白及其制备方法和用途
WO2016073456A1 (en) 2014-11-04 2016-05-12 The Trustees Of The University Of Pennsylvania Methods and compositions of a follicle stimulating hormone receptor immunoreceptor or chimeric antigen receptor

Also Published As

Publication number Publication date
DK3200815T3 (da) 2021-05-10
CN106999552B (zh) 2021-12-28
EP3200815A4 (en) 2018-04-25
HRP20210705T1 (hr) 2021-07-23
CN106999552A (zh) 2017-08-01
CN114150018A (zh) 2022-03-08
EP3200815B1 (en) 2021-03-03
US12384826B2 (en) 2025-08-12
US20190248862A1 (en) 2019-08-15
CA2989807C (en) 2023-07-04
CY1125797T1 (el) 2024-02-16
WO2016054153A1 (en) 2016-04-07
EP3200815A1 (en) 2017-08-09
PT3200815T (pt) 2021-05-07
US20170226176A1 (en) 2017-08-10
SMT202100273T1 (it) 2021-07-12
US20250340609A1 (en) 2025-11-06
SI3200815T1 (sl) 2021-11-30
HUE054673T2 (hu) 2021-09-28
US10259855B2 (en) 2019-04-16
US20220185861A1 (en) 2022-06-16
LT3200815T (lt) 2021-07-26
US11248033B2 (en) 2022-02-15
RS61929B1 (sr) 2021-06-30
ES2870607T3 (es) 2021-10-27
CA2989807A1 (en) 2016-04-07

Similar Documents

Publication Publication Date Title
IL296080B1 (en) Method for treating cancer
IL258955B1 (en) Cancer treatment preparations and methods
IL249065A0 (en) Combination therapies for the treatment of cancer
PL3200815T3 (pl) Sposoby i kompozycje do leczenia nowotworu
BR112017011771A2 (pt) métodos e composições para o tratamento de câncer
PL3377516T3 (pl) Kompozycja do leczenia nowotworu
PL3288581T3 (pl) Sposób leczenia nowotworu
PL3283527T3 (pl) Leczenie skojarzone nowotworów
PL3277270T3 (pl) Kompozycje i sposoby leczenia niedokrwistości
IL249658A0 (en) Methods of treating cancer using tigit inhibitors and anticancer agents
LT3277842T (lt) Vėžio pacientų gydymo būdai farneziltransferazės inhibitoriais
IL251890A0 (en) Combination immunotherapy approach for treatment of cancer
PT3142637T (pt) Formulações e métodos de tratamento de queratina
SG11201701723XA (en) Methods of treating liver disease
LT3119808T (lt) Antikūnų kompozicijos vėžio gydymui
IL258521B1 (en) Combination therapy for the treatment of cancer
DK3209696T3 (da) Fremgangsmåder og sammensætninger til diagnosticering og behandling af glioblastom
DK3194564T3 (da) Trichodermasammensætninger og anvendelsesfremgangsmåder
PT3622953T (pt) Tratamento combinado do cancro
PL3189074T3 (pl) Kompozycje oraz sposoby leczenia i zapobiegania zapaleniom
PL3393468T3 (pl) Metody leczenia niedoboru odporności
IL257764B (en) Methods for treatment of diseases
HUE040167T2 (hu) Rákkezelés
PL3397964T3 (pl) Kompozycje i sposoby do wykrywania i leczenia raka jajnika
EP4043567C0 (en) METHOD AND COMPOSITIONS FOR TREATMENT OF CANCER